Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease
Open Access
- 1 August 2021
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 14 (8)
Abstract
People of recent sub-Saharan African ancestry develop kidney failure much more frequently than other groups. A large fraction of this disparity is due to two coding sequence variants in the APOL1 gene. Inheriting two copies of these APOL1 risk variants, known as G1 and G2, causes high rates of focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy and hypertension-associated end-stage kidney disease. Disease risk follows a recessive mode of inheritance, which is puzzling given the considerable data that G1 and G2 are toxic gain-of-function variants. We developed coisogenic bacterial artificial chromosome (BAC) transgenic mice harboring either the wild-type (G0), G1 or G2 forms of human APOL1. Expression of interferon gamma (IFN-γ) via plasmid tail vein injection results in upregulation of APOL1 protein levels together with robust induction of heavy proteinuria and glomerulosclerosis in G1/G1 and G2/G2 but not G0/G0 mice. The disease phenotype was greater in G2/G2 mice. Neither heterozygous (G1/G0 or G2/G0) risk variant mice nor hemizygous (G1/−, G2/−) mice had significant kidney injury in response to IFN-γ, although the heterozygous mice had a greater proteinuric response than the hemizygous mice, suggesting that the lack of significant disease in humans heterozygous for G1 or G2 is not due to G0 rescue of G1 or G2 toxicity. Studies using additional mice (multicopy G2 and a non-isogenic G0 mouse) supported the notion that disease is largely a function of the level of risk variant APOL1 expression. Together, these findings shed light on the recessive nature of APOL1-nephropathy and present an important model for future studies.Keywords
Funding Information
- CORE (MD014726)
- U.S. Department of War (W81XWH-14-1-0333)
- National Institutes of Health (MD007092)
- Vertex Pharmaceutical
- Ellison Medical Foundation
This publication has 86 references indexed in Scilit:
- APOL1 Null Alleles from a Rural Village in India Do Not Correlate with GlomerulosclerosisPLOS ONE, 2012
- APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated NephropathyJournal of the American Society of Nephrology, 2011
- APOL1 Localization in Normal Kidney and Nondiabetic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- The APOL1 Gene and Allograft Survival after Kidney TransplantationAmerican Journal of Transplantation, 2011
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010
- Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHuman Genetics, 2010
- The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host–pathogen interactionsGenome Research, 2009
- HIV-Associated Nephropathy: Clinical Presentation, Pathology, and Epidemiology in the Era of Antiretroviral TherapySeminars in Nephrology, 2008
- STAT dynamicsCytokine & Growth Factor Reviews, 2007
- Pathophysiology of focal segmental glomerulosclerosisPediatric Nephrology, 2007